Non Comparative Study on Various Pulse Regimens (DCP, DAP and DMP) in Pemphigus: Our Experience

Area of Science:

• Immunodermatology
• Clinical Pharmacology
• Autoimmune Disease Treatment

Background:

• Pemphigus treatment has evolved since 1981, with Dexamethasone Cyclophosphamide Pulse (DCP) therapy as a cornerstone.
• Modifications such as Dexamethasone Azathioprine Pulse (DAP) and Dexamethasone Methotrexate Pulse (DMP) therapies have been explored.

Purpose of the Study:

• To evaluate the clinical experience with three distinct pulse steroid regimens for pemphigus management.
• Assessing the efficacy and limitations of DCP, DAP, and DMP therapies in a real-world setting.

Main Methods:

• Patients were assigned to conventional DCP, DAP (for reproductive age group), or DMP (for prolonged Phase I on DCP).
• Data on disease control, remission duration, and relapse rates were collected for each regimen.

Main Results:

• DCP therapy demonstrated an average Phase I duration of six months with a low relapse rate (3/30 in Phase IV).
• DAP therapy showed higher relapse rates (5/12 in Phase III, 4/12 in Phase IV).
• DMP therapy resulted in poor disease control, leading to discontinuation in three out of five patients.

Conclusions:

• DCP therapy remains the gold standard for pemphigus, providing the fastest and most durable remissions.
• DAP therapy may be less effective, with potential issues related to azathioprine dosing.
• DMP therapy is not a viable option for recalcitrant pemphigus, highlighting a need for alternative treatments.